WO2012150829A3 - Dérivé de triazolopyridine noble ou sels pharmaceutiquement acceptables de celui-ci, procédé de production de celui-ci, et composition pharmaceutique comprenant celui-ci - Google Patents

Dérivé de triazolopyridine noble ou sels pharmaceutiquement acceptables de celui-ci, procédé de production de celui-ci, et composition pharmaceutique comprenant celui-ci Download PDF

Info

Publication number
WO2012150829A3
WO2012150829A3 PCT/KR2012/003487 KR2012003487W WO2012150829A3 WO 2012150829 A3 WO2012150829 A3 WO 2012150829A3 KR 2012003487 W KR2012003487 W KR 2012003487W WO 2012150829 A3 WO2012150829 A3 WO 2012150829A3
Authority
WO
WIPO (PCT)
Prior art keywords
noble
pharmaceutically acceptable
pharmaceutical composition
production method
acceptable salts
Prior art date
Application number
PCT/KR2012/003487
Other languages
English (en)
Korean (ko)
Other versions
WO2012150829A2 (fr
Inventor
구일회
박지선
천광우
류동규
최정훈
김영하
조보영
이한창
김강전
김승현
구세광
Original Assignee
제일약품주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제일약품주식회사 filed Critical 제일약품주식회사
Priority claimed from KR1020120046919A external-priority patent/KR101360176B1/ko
Publication of WO2012150829A2 publication Critical patent/WO2012150829A2/fr
Publication of WO2012150829A3 publication Critical patent/WO2012150829A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un dérivé de triazolopyridine noble ou des sels pharmaceutiquement acceptables de celui-ci, un procédé de production de celui-ci, et une composition pharmaceutique comprenant celui-ci. Le dérivé de triazolopyridine noble de la présente invention inhibe GSK-3, et peut donc être utilement utilisé pour prévenir ou traiter des maladies associées à la démence, la maladie d'Alzheimer, la démence frontotemporale, le parkinsonisme, le complexe de Guam Parkinson-démence, la démence liée au VIH, ou des maladies associées à une pathologie des enchevêtrements neurofibrillaires.
PCT/KR2012/003487 2011-05-04 2012-05-03 Dérivé de triazolopyridine noble ou sels pharmaceutiquement acceptables de celui-ci, procédé de production de celui-ci, et composition pharmaceutique comprenant celui-ci WO2012150829A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2011-0042606 2011-05-04
KR20110042606 2011-05-04
KR10-2012-0046919 2012-05-03
KR1020120046919A KR101360176B1 (ko) 2011-05-04 2012-05-03 신규한 트리아졸로피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물

Publications (2)

Publication Number Publication Date
WO2012150829A2 WO2012150829A2 (fr) 2012-11-08
WO2012150829A3 true WO2012150829A3 (fr) 2012-12-27

Family

ID=47108150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/003487 WO2012150829A2 (fr) 2011-05-04 2012-05-03 Dérivé de triazolopyridine noble ou sels pharmaceutiquement acceptables de celui-ci, procédé de production de celui-ci, et composition pharmaceutique comprenant celui-ci

Country Status (1)

Country Link
WO (1) WO2012150829A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019043635A1 (fr) 2017-09-01 2019-03-07 Richter Gedeon Nyrt. Composés inhibiteurs de l'activité de d-amino acide oxydase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004772A1 (en) * 2005-06-17 2007-01-04 Chongqing Sun Triazolopyridine cannabinoid receptor 1 antagonists
WO2010117926A1 (fr) * 2009-04-07 2010-10-14 Schering Corporation Triazolopyridines substituées et leurs analogues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004772A1 (en) * 2005-06-17 2007-01-04 Chongqing Sun Triazolopyridine cannabinoid receptor 1 antagonists
WO2010117926A1 (fr) * 2009-04-07 2010-10-14 Schering Corporation Triazolopyridines substituées et leurs analogues

Also Published As

Publication number Publication date
WO2012150829A2 (fr) 2012-11-08

Similar Documents

Publication Publication Date Title
WO2012077932A3 (fr) Nouveau dérivé de pyrazole pyridine ou sels de qualité pharmaceutique de celui-ci, leur procédé de production, et composition pharmaceutique les contenant
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
WO2017132432A8 (fr) Dérivés de benzimidazoles utilisés comme modulateurs de ror-gamma
PH12015502002A1 (en) Tripeptide epoxy ketone protease inhibitors
WO2011093826A3 (fr) Formulations effervescentes comprenant du céfaclor et de l'acide clavulanique comme principes actifs
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
PH12016502103A1 (en) Novel disubstituted 1,2, 4-triazine compound
MX2009010407A (es) Derivados fluorados de deferiprona.
SG10201901242PA (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
EA032951B1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
JO3326B1 (ar) مثبطات إيبوكسي كيتون بروتياز ثلاثي الببتيد
CY1124115T1 (el) Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες
ECSP13012847A (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación.
IN2014DN09347A (fr)
WO2014203275A3 (fr) Procédé amélioré pour la préparation d'apixaban et de ses intermédiaires
PH12015500012B1 (en) Benzodioxole derivative and preparation method and use thereof
IN2015DN01023A (fr)
WO2017182873A3 (fr) Composés foldamères de peptide-oligourée et leurs procédés d'utilisation
WO2011159124A3 (fr) Nouveau dérivé de benzoxazole présentant une activité inhibitrice contre l'interleukine 6, procédé pour le préparer, et composition pharmaceutique le contenant
WO2014167577A3 (fr) Synthèse du dabigatran
JO3483B1 (ar) 4-هيدروكسي -2- مثيل -5- (بروبان-2-يليدين) هكس - 3- ين حلقي كربالدهيد للوقاية من ومعالجة مرض معرفي أو تنكسي عصبي أو عصبي
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
WO2015082590A3 (fr) Dérivés de bis-mmf
WO2012150829A3 (fr) Dérivé de triazolopyridine noble ou sels pharmaceutiquement acceptables de celui-ci, procédé de production de celui-ci, et composition pharmaceutique comprenant celui-ci
WO2015166419A3 (fr) Procédé d'obtention et composition pharmaceutique de kétorolac trométhamine et de chlorhydrate de tramadol à administration sublinguale pour soulager la douleur

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12779487

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12779487

Country of ref document: EP

Kind code of ref document: A2